Real questions from health communities, answered with cited research from PubMed and Vellito's article corpus. Plain language, no medical advice. How this works.
Lifileucel is a cell therapy that uses your own immune cells to fight metastatic melanoma after other treatments fail. It involves removing tumor cells, growing immune cells in a…
Research shows that targeting shared molecular pathways like Siglec signaling, mitochondrial cell death, and immune metabolism offers new ways to treat both autoimmune disorders…
Siglec signaling pathways are linked to autoimmune and inflammatory disorders, neurodegeneration, and infections in addition to cancer.
Adjuvant chemotherapy regimens for early-stage breast cancer have distinct safety profiles; TAC causes more febrile neutropenia, while AC→T leads to more neuropathy and hand-foot…
Activity pacing interventions show a small but not statistically significant effect on cancer-related fatigue overall, but may significantly help patients undergoing chemotherapy.
Yes, acupuncture appears to significantly improve cancer-related fatigue, with recent meta-analyses showing moderate benefit, though study quality is limited.
PROTACs are not yet available as approved treatments for most oncology conditions, though one specific drug, vepdegestrant, is in clinical trials for advanced breast cancer.
Yes, radical perineal prostatectomy typically causes less blood loss than the retropubic approach for localized prostate cancer, based on direct comparative studies.
Artificial intelligence helps kidney cancer patients by improving tumor detection on scans, planning robotic surgeries, and predicting surgical outcomes to reduce complications.
Yes, the 2025 EAU guidelines update kidney cancer care with new recommendations on stereotactic body radiotherapy, adjuvant therapy, and systemic treatments for clear-cell and…
In nonsquamous advanced NSCLC, camrelizumab was linked to a higher risk of disease progression and death than pembrolizumab in second-line or later treatment, based on one…
For advanced NSCLC, immunotherapy (especially pembrolizumab) is highly effective for high PD-L1 tumors, while chemotherapy remains a backbone; combining both may improve outcomes.
Yes, real-world data from over 17,500 patients shows pembrolizumab is effective as first-line treatment for advanced NSCLC with high PD-L1 (≥50%), with median overall survival of…
Central vascular ligation (CVL) during complete mesocolic excision improves disease-free and overall survival in colon cancer, but the benefit may be limited to certain tumor…
The meta-analysis included 6,129 patients with advanced solid tumors who received immune checkpoint inhibitors across 29 studies.
Yes, Revlimid (lenalidomide) is FDA-approved for previously treated follicular lymphoma, specifically in combination with rituximab.
Abexinostat shows a 69.5% objective response rate in relapsed follicular lymphoma, based on a phase 2 trial.
Fixed-duration subcutaneous mosunetuzumab shows a favorable safety profile with lower rates of severe immune-related adverse events compared to the intravenous version in…
Yes, an MRI nomogram that combines habitat radiomics and clinical factors can predict high-risk LARC more accurately than single-feature models, helping guide treatment decisions.
Yes, photobiomodulation significantly reduces the risk of severe oral mucositis in head and neck cancer patients, with a 54% risk reduction shown in a recent meta-analysis.
About 48% of breast cancer patients experience chemotherapy-induced nausea and vomiting, with higher risk in younger patients and those with motion sickness history.
Yes, zinc supplements may help prevent oral mucositis after chemoradiotherapy, especially when started early and used topically, but evidence is limited.
For high-risk NMIBC, BCG plus mitomycin does not improve disease-free survival compared to BCG alone, and may increase toxicity.
Intravesical gemcitabine/docetaxel may offer similar or better recurrence-free survival with fewer side effects compared to BCG for non-muscle invasive bladder cancer, but…
We pull real patient questions from public Reddit health communities (r/AskDocs, r/diabetes, r/menopause, etc.). Each question is rewritten into a generic medical question (no personal details), then answered by an AI using only cited sources from Vellito's article database and PubMed. A second AI independently scores each answer for accuracy and citation fidelity before publication. Answers below the safety threshold or touching emergency, dosing, or pediatric topics are queued for human review and never auto-published.
This is not medical advice. Always speak with your own doctor before making decisions about your health.